Get the Stockscreener App
3.47
4.67%
-0.17
Atea Pharmaceuticals Inc stock is traded at $3.47, with a volume of 313.68K.
It is down -4.67% in the last 24 hours and down -3.61% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$3.64
Open:
$3.59
24h Volume:
313.68K
Relative Volume:
0.75
Market Cap:
$296.96M
Revenue:
$351.37M
Net Income/Loss:
$-174.01M
P/E Ratio:
-1.6763
EPS:
-2.07
Net Cash Flow:
$-126.94M
1W Performance:
-11.03%
1M Performance:
-3.61%
6M Performance:
+13.40%
1Y Performance:
-4.41%
1-Day Range:
$3.46
$3.685
1-Week Range:
$3.46
$4.02
52-Week Range:
$2.455
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.47 | 311.51M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Regression analysis insights on Atea Pharmaceuticals Inc. performanceEquity Forecast with Predictive AI Screener - Newser
Why Atea Pharmaceuticals Inc. stock attracts strong analyst attentionReal Market Tracker with Price Action Tools - Newser
Is Atea Pharmaceuticals Inc. forming a bottoming baseConservative Investment Setup and Risk Analysis - Newser
Atea Pharmaceuticals Inc. stock volume spike explainedFree Accurate Buy Point for Momentum Stocks - Newser
How many analysts rate Atea Pharmaceuticals Inc. as a “Buy”Value Investing Guidance To Watch Now - jammulinksnews.com
Custom watchlist performance reports with Atea Pharmaceuticals Inc.Free Chart Driven High Reward Trading Setup - Newser
What makes Atea Pharmaceuticals Inc. stock price move sharplyTop Growth Entry Points To Watch Now - jammulinksnews.com
What catalysts could drive Atea Pharmaceuticals Inc. stock higher in 2025Entry Signal Guidance That Work - jammulinksnews.com
When is the best time to exit Atea Pharmaceuticals Inc.Pre-Market Stock Movement Summary and Review - Newser
Quantitative breakdown of Atea Pharmaceuticals Inc. recent moveMarket Sentiment Tracker with Smart Alerts - Newser
Atea Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayAI Risk Optimized Trade Forecast Planner - Newser
Using data filters to optimize entry into Atea Pharmaceuticals Inc.Quarterly Investment Outlook and Key Summary - Newser
Institutional scanner results for Atea Pharmaceuticals Inc.Free Short Term Trading Opportunity Watch - Newser
Atea Pharmaceuticals to Host Second Quarter 2025 Financial - GlobeNewswire
Atea Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Antiviral Drug Pipeline - Stock Titan
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 - GlobeNewswire Inc.
Is Atea Pharmaceuticals Inc. a Top Dividend Stock to Watch in 2025Free Momentum Based Equity Trading Plan - Newser
Published on: 2025-07-29 16:38:14 - Newser
Fibonacci Support Holding Strong in Atea Pharmaceuticals Inc.Real Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Long term hold vs stop loss in Atea Pharmaceuticals Inc.Free Swing Trading Plan With Smart Signals - Newser
Candlestick Reversal Detected on Atea Pharmaceuticals Inc.’s ChartOversold Recovery Opportunity Stocks Attract Buyers - metal.it
Is Atea Pharmaceuticals Inc. Forming a Consolidation BaseSwing Trading Plan With Smart Signals in Review - metal.it
Is Atea Pharmaceuticals Inc. a growth stock or a value stockMarket Forecast Picks That Work - jammulinksnews.com
Atea Pharmaceuticals Inc. Price Targets Raised After ReboundTechnical Stock Breakout Predictions Signal Entry Points - metal.it
What institutional investors are buying Atea Pharmaceuticals Inc. stockDiscover top stock picks for aggressive growth - jammulinksnews.com
Institutional scanner results for Atea Pharmaceuticals Inc. Free Daily Smart Money Movement Monitor - Newser
How volatile is Atea Pharmaceuticals Inc. stock compared to the marketTriple-digit profit margins - jammulinksnews.com
How does Atea Pharmaceuticals Inc. compare to its industry peersDouble-digit growth - jammulinksnews.com
When is Atea Pharmaceuticals Inc. stock expected to show significant growthUnlock powerful portfolio optimization tools - jammulinksnews.com
What drives Atea Pharmaceuticals Inc. stock priceExceptional earning trajectories - PrintWeekIndia
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
| BERGER FRANKLIN M | Director |
Dec 10 '24 |
Sale |
2.85 |
359,606 |
1,023,475 |
451,897 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):